Literature DB >> 17998333

A mouse gene that coordinates epigenetic controls and transcriptional interference to achieve tissue-specific expression.

Alexandra C Racanelli1, Fiona B Turner, Lin-Ying Xie, Shirley M Taylor, Richard G Moran.   

Abstract

The mouse fpgs gene uses two distantly placed promoters to produce functionally distinct isozymes in a tissue-specific pattern. We queried how the P1 and P2 promoters were differentially controlled. DNA methylation of the CpG-sparse P1 promoter occurred only in tissues not initiating transcription at this site. The P2 promoter, which was embedded in a CpG island, appeared open to transcription in all tissues by several criteria, including lack of DNA methylation, yet was used only in dividing tissues. The patterns of histone modifications over the two promoters were very different: over P1, histone activation marks (acetylated histones H3 and H4 and H3 trimethylated at K4) reflected transcriptional activity and apparently reinforced the effects of hypomethylated CpGs; over P2, these marks were present in tissues whether P2 was active, inactive, or engaged in assembly of futile initiation complexes. Since P1 transcriptional activity coexisted with silencing of P2, we sought the mechanism of this transcriptional interference. We found RNA polymerase II, phosphorylated in a pattern consistent with transcriptional elongation, and only minimal levels of initiation factors over P2 in liver. We concluded that mouse fpgs uses DNA methylation to control tissue-specific expression from a CpG-sparse promoter, which is dominant over a downstream promoter masked by promoter occlusion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17998333      PMCID: PMC2223435          DOI: 10.1128/MCB.01088-07

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  75 in total

Review 1.  Polyglutamation of methotrexate. Is methotrexate a prodrug?

Authors:  B A Chabner; C J Allegra; G A Curt; N J Clendeninn; J Baram; S Koizumi; J C Drake; J Jolivet
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

2.  De novo methylation of the MyoD1 CpG island during the establishment of immortal cell lines.

Authors:  P A Jones; M J Wolkowicz; W M Rideout; F A Gonzales; C M Marziasz; G A Coetzee; S J Tapscott
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

3.  A fraction of the mouse genome that is derived from islands of nonmethylated, CpG-rich DNA.

Authors:  A Bird; M Taggart; M Frommer; O J Miller; D Macleod
Journal:  Cell       Date:  1985-01       Impact factor: 41.582

4.  Impaired methotrexate polyglutamylation in a human leukemia cell line resistant to short-term, high-dose methotrexate.

Authors:  E Mini; G Pizzorno; M Coronnello; J J McGuire; T Mazzei; P Periti; J R Bertino
Journal:  Pharmacol Res Commun       Date:  1988-05

5.  DNA methylation affects the formation of active chromatin.

Authors:  I Keshet; J Lieman-Hurwitz; H Cedar
Journal:  Cell       Date:  1986-02-28       Impact factor: 41.582

6.  Transcriptional interference and termination between duplicated alpha-globin gene constructs suggests a novel mechanism for gene regulation.

Authors:  N J Proudfoot
Journal:  Nature       Date:  1986 Aug 7-13       Impact factor: 49.962

7.  Prolonged inhibition of DNA synthesis associated with the accumulation of methotrexate polyglutamates by cultured human cells.

Authors:  D S Rosenblatt; V M Whitehead; N Vera; A Pottier; M Dupont; M J Vuchich
Journal:  Mol Pharmacol       Date:  1978-11       Impact factor: 4.436

8.  Unusual methylation pattern of the alpha 2 (l) collagen gene.

Authors:  C McKeon; H Ohkubo; I Pastan; B de Crombrugghe
Journal:  Cell       Date:  1982-05       Impact factor: 41.582

9.  Methotrexate polyglutamate synthesis by cultured human breast cancer cells.

Authors:  R L Schilsky; B D Bailey; B A Chabner
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

10.  Non-methylated CpG-rich islands at the human alpha-globin locus: implications for evolution of the alpha-globin pseudogene.

Authors:  A P Bird; M H Taggart; R D Nicholls; D R Higgs
Journal:  EMBO J       Date:  1987-04       Impact factor: 11.598

View more
  7 in total

1.  Silencing and transcriptional properties of the imprinted Airn ncRNA are independent of the endogenous promoter.

Authors:  Stefan H Stricker; Laura Steenpass; Florian M Pauler; Federica Santoro; Paulina A Latos; Ru Huang; Martha V Koerner; Mathew A Sloane; Katarzyna E Warczok; Denise P Barlow
Journal:  EMBO J       Date:  2008-11-13       Impact factor: 11.598

2.  Transcriptional interference by RNA polymerase pausing and dislodgement of transcription factors.

Authors:  Adam C Palmer; J Barry Egan; Keith E Shearwin
Journal:  Transcription       Date:  2011 Jan-Feb

3.  Humanizing mouse folate metabolism: conversion of the dual-promoter mouse folylpolyglutamate synthetase gene to the human single-promoter structure.

Authors:  Chen Yang; Lin-Ying Xie; Jolene J Windle; Shirley M Taylor; Richard G Moran
Journal:  FASEB J       Date:  2014-02-14       Impact factor: 5.191

4.  XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center.

Authors:  Franco M Muggia; Godefridus J Peters; Joseph R Landolph
Journal:  Mol Cancer Ther       Date:  2009-05-05       Impact factor: 6.261

5.  Intragenic transcriptional interference regulates the human immune ligand MICA.

Authors:  Da Lin; Thomas K Hiron; Christopher A O'Callaghan
Journal:  EMBO J       Date:  2018-04-11       Impact factor: 11.598

Review 6.  Gene regulation by the act of long non-coding RNA transcription.

Authors:  Aleksandra E Kornienko; Philipp M Guenzl; Denise P Barlow; Florian M Pauler
Journal:  BMC Biol       Date:  2013-05-30       Impact factor: 7.431

7.  Epigenetic Modifications of the PGC-1α Promoter during Exercise Induced Expression in Mice.

Authors:  Timothy L Lochmann; Ravindar R Thomas; James P Bennett; Shirley M Taylor
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.